Cargando…

Luminescent multiplex viability assay for Trypanosoma brucei gambiense

BACKGROUND: New compounds for the treatment of human African trypanosomiasis (HAT) are urgently required. Trypanosoma brucei (T.b.) gambiense is the leading cause of HAT, yet T.b. gambiense is often not the prime target organism in drug discovery. This may be attributed to the difficulties in handli...

Descripción completa

Detalles Bibliográficos
Autores principales: Van Reet, Nick, Pyana, Pati, Rogé, Stijn, Claes, Filip, Büscher, Philippe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3728213/
https://www.ncbi.nlm.nih.gov/pubmed/23856321
http://dx.doi.org/10.1186/1756-3305-6-207
_version_ 1782278824639070208
author Van Reet, Nick
Pyana, Pati
Rogé, Stijn
Claes, Filip
Büscher, Philippe
author_facet Van Reet, Nick
Pyana, Pati
Rogé, Stijn
Claes, Filip
Büscher, Philippe
author_sort Van Reet, Nick
collection PubMed
description BACKGROUND: New compounds for the treatment of human African trypanosomiasis (HAT) are urgently required. Trypanosoma brucei (T.b.) gambiense is the leading cause of HAT, yet T.b. gambiense is often not the prime target organism in drug discovery. This may be attributed to the difficulties in handling this subspecies and the lack of an efficient viability assay to monitor drug efficacy. METHODS: In this study, a T.b. gambiense strain, recently isolated in the D.R. Congo, was made bioluminescent by transfection with Renilla luciferase (RLuc) without altering its in vitro and in vivo growth characteristics. A luminescent multiplex viability assay (LMVA), based on measurement of the Renilla luciferase activity and the ATP content of the cells within the same experiment, was investigated as an alternative to the standard fluorimetric resazurin viability assay for drug sensitivity testing of T.b. gambiense. RESULTS: In a 96-well format, the RLuc transfected strain showed a detection limit of 2 × 10(4) cells ml(-1) for the Renilla luciferase measurement and 5 × 10(3) cells ml(-1) for the ATP measurement. Both assays of the LMVA showed linearity up to 10(6) cells ml(-1) and correlated well with the cell density during exponential growth of the long slender bloodstream forms. The LMVA was compared to the fluorimetric resazurin viability assay for drug sensitivity testing of pentamidine, eflornithine, nifurtimox and melarsoprol with both the wild type and the RLuc transfected population. For each drug, the IC(50) value of the RLuc population was similar to that of the wild type when determined with either the fluorimetric resazurin method or the LMVA. For eflornithine, nifurtimox and melarsoprol we found no difference between the IC(50) values in both viability assays. In contrast, the IC(50) value of pentamidine was higher when determined with the fluorimetric resazurin method than in both assays of the LMVA. CONCLUSIONS: LMVA has some advantages for viability measurement of T.b. gambiense: it requires less incubation time for viability detection than the fluorimetric resazurin assay and in LMVA, two sensitive and independent viability assays are performed in the same experiment.
format Online
Article
Text
id pubmed-3728213
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-37282132013-08-01 Luminescent multiplex viability assay for Trypanosoma brucei gambiense Van Reet, Nick Pyana, Pati Rogé, Stijn Claes, Filip Büscher, Philippe Parasit Vectors Research BACKGROUND: New compounds for the treatment of human African trypanosomiasis (HAT) are urgently required. Trypanosoma brucei (T.b.) gambiense is the leading cause of HAT, yet T.b. gambiense is often not the prime target organism in drug discovery. This may be attributed to the difficulties in handling this subspecies and the lack of an efficient viability assay to monitor drug efficacy. METHODS: In this study, a T.b. gambiense strain, recently isolated in the D.R. Congo, was made bioluminescent by transfection with Renilla luciferase (RLuc) without altering its in vitro and in vivo growth characteristics. A luminescent multiplex viability assay (LMVA), based on measurement of the Renilla luciferase activity and the ATP content of the cells within the same experiment, was investigated as an alternative to the standard fluorimetric resazurin viability assay for drug sensitivity testing of T.b. gambiense. RESULTS: In a 96-well format, the RLuc transfected strain showed a detection limit of 2 × 10(4) cells ml(-1) for the Renilla luciferase measurement and 5 × 10(3) cells ml(-1) for the ATP measurement. Both assays of the LMVA showed linearity up to 10(6) cells ml(-1) and correlated well with the cell density during exponential growth of the long slender bloodstream forms. The LMVA was compared to the fluorimetric resazurin viability assay for drug sensitivity testing of pentamidine, eflornithine, nifurtimox and melarsoprol with both the wild type and the RLuc transfected population. For each drug, the IC(50) value of the RLuc population was similar to that of the wild type when determined with either the fluorimetric resazurin method or the LMVA. For eflornithine, nifurtimox and melarsoprol we found no difference between the IC(50) values in both viability assays. In contrast, the IC(50) value of pentamidine was higher when determined with the fluorimetric resazurin method than in both assays of the LMVA. CONCLUSIONS: LMVA has some advantages for viability measurement of T.b. gambiense: it requires less incubation time for viability detection than the fluorimetric resazurin assay and in LMVA, two sensitive and independent viability assays are performed in the same experiment. BioMed Central 2013-07-15 /pmc/articles/PMC3728213/ /pubmed/23856321 http://dx.doi.org/10.1186/1756-3305-6-207 Text en Copyright © 2013 Van Reet et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Van Reet, Nick
Pyana, Pati
Rogé, Stijn
Claes, Filip
Büscher, Philippe
Luminescent multiplex viability assay for Trypanosoma brucei gambiense
title Luminescent multiplex viability assay for Trypanosoma brucei gambiense
title_full Luminescent multiplex viability assay for Trypanosoma brucei gambiense
title_fullStr Luminescent multiplex viability assay for Trypanosoma brucei gambiense
title_full_unstemmed Luminescent multiplex viability assay for Trypanosoma brucei gambiense
title_short Luminescent multiplex viability assay for Trypanosoma brucei gambiense
title_sort luminescent multiplex viability assay for trypanosoma brucei gambiense
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3728213/
https://www.ncbi.nlm.nih.gov/pubmed/23856321
http://dx.doi.org/10.1186/1756-3305-6-207
work_keys_str_mv AT vanreetnick luminescentmultiplexviabilityassayfortrypanosomabruceigambiense
AT pyanapati luminescentmultiplexviabilityassayfortrypanosomabruceigambiense
AT rogestijn luminescentmultiplexviabilityassayfortrypanosomabruceigambiense
AT claesfilip luminescentmultiplexviabilityassayfortrypanosomabruceigambiense
AT buscherphilippe luminescentmultiplexviabilityassayfortrypanosomabruceigambiense